Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 8/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073652 | 1.00 | NR1H2 (0.38) | NR1H2HSD11B1NR1H3CYP1A2POLB | |
| SCHEMBL12213318 | 0.88 | NR1H2 (0.41) | NR1H2HSD11B1CYP1A2POLBCYP3A4 | |
| SCHEMBL1724522 | 0.88 | NR1H2 (0.41) | NR1H2HSD11B1CYP1A2POLBCYP3A4 | |
| SCHEMBL12204166 | 0.88 | NR1H2 (0.41) | NR1H2HSD11B1CYP1A2POLBCYP3A4 | |
| SCHEMBL2523332 | 0.82 | NR1H2 (0.41) | NR1H2HSD11B1CYP1A2POLBCYP3A4 | |
| SCHEMBL3725714 | 0.82 | NR1H2 (0.48) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL8065917 | 0.82 | NR1H2 (0.48) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL12213289 | 0.82 | NR1H2 (0.41) | NR1H2HSD11B1CYP1A2POLBCYP3A4 | |
| SCHEMBL1085466 | 0.82 | NR1H2 (0.48) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL8070913 | 0.82 | NR1H2 (0.48) | NR1H2CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | NR1H2 2409/4885HSD11B1 3632/4885NR1H3 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.